Michael Aldridge, Seasoned Biotech Executive, Appointed CEO of Focal Medical
Michael joins Focal Medical with more than 25 years of experience in the biopharma industry.
- Michael joins Focal Medical with more than 25 years of experience in the biopharma industry.
- View the full release here: https://www.businesswire.com/news/home/20221101006248/en/
Focal Medical appoints Michael Aldridge CEO (Photo: Business Wire)
Focal Medical is the new name of Advanced Chemotherapy Technologies. - Focal Medicals corporate rebranding is a function of a strategic shift towards broader product applications of its targeted drug delivery technology.
- To date, Focal Medical has raised over $20 million in equity and grant funding.